40 results about "Distant metastasis" patented technology

The invention provides a gastric cancer TNM staging automation method and system based on a large language model. The method comprises the steps that a medical data set related to gastric cancer of a patient is acquired; preprocessing the medical data set; inputting the preprocessed medical data set into a trained large language model; extracting examination conclusions in the preprocessed medical data set, splicing all diagnosis conclusions into a long text for input, and inserting special separators between different sources for distinguishing; performing feature extraction on the long text input to generate a feature vector; probability inference is carried out after suspicious remote transfer labeling in the feature vectors; carrying out conflict statement resolution and credibility judgment on the feature vectors, and then carrying out TNM stage classification; and outputting the TNM staging result of the patient. The method has the beneficial effects that full-process automatic processing from medical data set acquisition, preprocessing and feature extraction to final TNM stage classification is realized.

The invention relates to the technical field of medical data analysis and machine learning. The invention discloses a far-end metastasis prediction system based on various examinations of a gastric cancer patient. The far-end metastasis prediction system comprises a data acquisition module for acquiring preoperative data of the gastric cancer patient; the preprocessing module cleans the normalized data; the feature selection module is used for screening overlapped features by using LassoCV, recursive feature elimination and Boruta algorithms to establish vectors; the model training module takes the feature vectors as input, and builds various models through automatic grid parameter searching and layered nested cross validation; the screening module selects an optimal model and performs multi-dimensional evaluation optimization; and the decision support module develops an online prediction or intranet generation result. The gastric cancer patient imaging, endoscope and blood multi-modal data are integrated, a multi-algorithm collaborative feature screening and machine learning model is constructed, through cross validation, parameter optimization and multi-dimensional evaluation, the prediction accuracy and reliability are improved, and the problem that traditional single inspection is insufficient in precision is solved.

Presented herein are systems and methods that provide automated analysis of 3D images to classify representations of lesions identified therein. In particular, in certain embodiments, approaches described herein allow hotspots representing lesions to be classified based on their spatial relationship with (e.g., whether they are in proximity to, overlap with, or are located within) one or more pelvic lymph node regions in detailed fashion.

This invention discloses the application of integrin αv inhibitors combined with γ-secretase inhibitors in the preparation of drugs for treating tumors. The study found that the combined use of integrin αv inhibitors and γ-secretase inhibitors in tumor treatment exhibits a synergistic effect, not only inhibiting in situ tumor growth but also significantly suppressing tumor invasion, distant metastasis, and other malignant progression, thus helping to slow tumor progression, improve treatment efficacy, and enhance patient prognosis. Furthermore, the study found that the combined use of integrin αv inhibitors and γ-secretase inhibitors can reduce the production of the intracellular free domain of integrin αv and inhibit the activation of the classical downstream pathway of integrin αv. The combined use of integrin αv inhibitors and γ-secretase inhibitors shows broad application prospects in tumor treatment.

The application discloses a nasopharyngeal carcinoma prognosis feature determination method, system and device and a storage medium. The method comprises the following steps: pathological image preprocessing, color normalization based on dye separation is used to standardize the dyeing of the pathological image; a segmentation network is used to automatically segment the lesion area of the preprocessed pathological image to obtain a segmented image; the segmented image is cropped to obtain a target image block; principal component analysis is used to reduce the dimension of the target image block to obtain reduced dimension data; a clustering algorithm is used to perform unsupervised autonomous learning on the reduced dimension data to obtain pathological image features; and finally, the pathological image features are screened through feature inspection to determine a prognosis pathological feature set. The application can obtain and screen key image features of pathological images closely related to local area recurrence and distant metastasis of nasopharyngeal carcinoma from pathological images to assist in prognosis prediction of nasopharyngeal carcinoma, and can be widely applied to the technical field of image processing.

The invention belongs to the technical field of biological medicine, and particularly relates to application of coniferyl aldehyde in preparation of anti-cancer drugs. The invention discloses application of coniferyl aldehyde in preparation of anti-cancer drugs, coniferyl aldehyde can significantly inhibit invasion and migration ability of hepatocellular carcinoma cells, cancer cells cannot break through primary parts through key links such as interference of movement and adhesion of the cancer cells and degradation of extracellular matrixes, invasion of tumors to surrounding tissues is reduced, and the anti-cancer effect is improved. The occurrence rate of remote metastasis is reduced, the non-metastasis lifetime of the patient is prolonged, and more treatment time and survival opportunities are won for the patient; a large number of cell experiments and animal experiments prove that the medicine has no obvious liver and kidney toxicity under the treatment dosage, the tolerance of a patient to treatment is improved, the smooth proceeding of the treatment process is guaranteed, and the living quality of the patient is effectively improved.

The present invention discloses a SEC63 fragment and its application in the preparation of liver cancer diagnosis and / or treatment drugs. The amino acid sequence of the SEC63 fragment is shown in SEQ ID NO.1, which can be used as a marker or target for the preparation of drugs for diagnosis and / or treatment of liver cancer, liver cancer metastasis and / or liver cancer prognosis assessment. The present invention first discovered that the expression level of the SEC63 fragment is significantly positively correlated with lymph node metastasis and distant metastasis of liver cancer, and that patients with high expression of the SEC63 fragment have a poor prognosis. Further studies have found that inhibitors of the SEC63 fragment can significantly inhibit the migration and invasion ability of liver cancer cells. Therefore, the SEC63 fragment can be used as a liver cancer treatment target and diagnostic biomarker for liver cancer patient prognosis monitoring and liver cancer treatment, providing new ideas and strategies for treatment-related drugs and diagnostic products.

The invention discloses an in-situ'tumor capture 'type electrostatic spinning patch as well as a preparation method and application thereof. The invention relates to an in-situ'tumor capture 'type electrostatic spinning patch for sequential treatment in and after pancreatic cancer resection. The electrostatic spinning patch comprises a gelatin / hyaluronic acid-based hemostatic sponge layer with a capture function, a gemcitabine slow-release layer and a polycaprolactone backing layer. According to the invention, the dual core requirements of hemostasis and cancer resistance during operation and after operation are integrated, and a long-acting protective barrier is constructed at the local part of the operation through continuous drug delivery. Therefore, the efficiency of removing residual lesions is remarkably improved, local recurrence and distant metastasis of tumors can be effectively prevented, and finally a safer, more lasting and more comprehensive comprehensive treatment new strategy is provided for pancreatic cancer postoperative patients.

The invention belongs to the field of polymer chemistry and biomedical engineering, and discloses a construction method and application of a biomimetic membrane coated drug-loaded nano system. According to the system disclosed by the invention, small-molecule traditional Chinese medicine (sinomenine) is loaded in mesopores, and homologous cell membranes wrap drug-loaded nanoparticles to obtain a final nano-drug system which can effectively and passively target nasopharyngeal carcinoma cells. The sinomenine can cooperate with photothermal therapy to jointly induce mitochondrial injury, promote cell apoptosis and cause ICD immunoreaction, the sinomenine inhibits PD-L1 expression to relieve immunosuppression of T cells, meanwhile, infiltration of cytotoxic T cells in tumor sites is increased, distant metastasis of nasopharyngeal carcinoma can be inhibited by inhibiting MMPs and PD-L1, and the nasopharyngeal carcinoma can be inhibited by inhibiting MMPs and PD-L1. Therefore, the effects of enhancing nasopharynx cancer immunotherapy and inhibiting metastasis are achieved.

The invention relates to the technical field of biological medicine, and particularly discloses application of an ICAM1 inhibitor in preparation of a nasopharynx cancer resistant circulating tumor cell cluster preparation. According to the application, expression of a shRNA silent gene ICAM1 is utilized, in-vitro experiments prove that proliferation, migration and invasion ability of nasopharyngeal carcinoma cells can be remarkably reduced by inhibiting the ICAM1, formation of circulating tumor cell clusters and angiogenesis are inhibited, after the nasopharyngeal carcinoma cells are treated by cis-platinum drugs, the activity of ICAM1 silent group cells is remarkably reduced, and the activity of the ICAM1 silent group cells is remarkably reduced. Experimental results show that a relatively low ICAM1 expression level is related to relatively high chemotherapeutic drug sensitivity. The ICAM1 inhibitor shICAM1 provided by the invention has important application value in preparation of a preparation for specifically targeting nasopharyngeal carcinoma circulating tumor cell clusters, and a brand new treatment scheme is provided for solving the problem of nasopharyngeal carcinoma distant metastasis.

The utility model relates to the technical field of tumor cell metastasis models, in particular to a breast cancer circulating tumor cell remote metastasis model which comprises a base and a fixing rod, the fixing rod is fixedly connected to the base, the fixing rod is fixedly connected with a brain metastasis model, a placing component is installed on the brain metastasis model, and the placing component is fixedly connected with the brain metastasis model. The placing part comprises an inclined plate, a fixed plate, a movable plate, a pressed plate, a straight spring and a collecting box, the inclined plate is fixedly connected in the brain metastasis model, the clamping plate clamps small balls with different colors through the matching effect of the extrusion rod, the movable plate, the collecting box and other parts, the small balls can be taken out by pulling the clamping plate, and the small balls can be conveniently taken out. And residual water is left in the collecting box, so that the small balls can be quickly taken out, meanwhile, no water drips on the outer surface of the model, the situation that the transparency of the model is affected by water marks generated on the outer surface of the model due to water dripping is avoided, and the transparency of the organ model and the cleanliness of a placement environment are guaranteed.

The disclosure relates to methods for treating melanoma with combinations of intratumoral agents and surgery, and methods for improving recurrence free survival and distant metastasis free survival in treated patients.

A research method for the regulatory mechanism of primary breast cancer on distant metastasis, miRNA-210 is intervened in lentiviral transfection of breast cancer cells, changes in Bcl-2 protein expression are detected, Bcl-2 gene luciferase reporter gene plasmid vectors containing miRNA-210 binding sites are constructed, and luciferase reporter gene detection experiments are performed after transfection of breast cancer cells to determine the regulatory relationship between the two; nude mouse tumor-bearing animal model is constructed, primary lesion tissue exosomes are injected into the center of the tumor, changes in tumor volume are recorded, and tumor blocks are taken to detect tumor cell autophagy and cell proliferation; Luciferase reporter gene detection experiments are used to determine the effect of primary lesion tissue exosome miRNA-210 on breast cancer cell proliferation in the in vivo environment, and whether this effect is related to the regulated target cell autophagy. The present invention provides an objective basis for clinical prevention and treatment of distant metastasis of breast cancer by regulating autophagy.

A technology is described which provides a platform for improving the penetration into tumors in a subject of cancer treatment and cancer imaging agents for greater patient benefit. The invention in particular overcomes two challenges for use of tumor targeting methods for solid tumors: poor penetration and the immunosuppressive nature of the tumor microenvironment. The platform described here allows long-term, in vivo production of iRGD. In a preferred embodiment, CAR-T cells are engineered to secrete iRGD, a tumor-penetrating peptide to achieve tissue-penetrating delivery of drugs and imaging agents in a tumor-specific manner. The peptide acutely permeabilizes the tumor vasculature by binding to αv integrins and neuropilin, but in a tumor-specific manner. This method produces a modification in the tumor microenvironment that enhances drug access into the tumor, prevents distant metastasis of the tumor cells, and allows long-term iRGD therapy without the need for repeated injections of iRGD.

This invention discloses the application of TTK in predicting the prognosis of anaplastic thyroid cancer. It provides a method for accurately assessing the prognosis of anaplastic thyroid cancer patients by calculating a predicted value based on the expression of TTK in tumor tissue and the presence of distant metastasis. This method is simple to use and can provide a basis for clinically determining whether more proactive treatment measures should be taken for anaplastic thyroid cancer patients. This helps improve the prognosis of anaplastic thyroid cancer patients and avoid unnecessary medical expenses, thus addressing the shortcomings of existing technologies.

The invention relates to the technical field of biological medicines, and discloses a FAP-targeted polymeric compound as well as a preparation method and application thereof. The chemical structure of the FAP-targeting polymeric compound is shown as any one of formulas (1)-(3), and the FAP-targeting polymeric compound comprises 3-6 targeting parts of fibroblast activating protein alpha (FAP-alpha). Compared with the existing compound, the FAP-targeted polymeric compound provided by the invention has higher tumor uptake and longer tumor residence time; in the diagnosis and treatment of FAP positive tumors, the FAP-targeted polymeric compound can clearly display the position and range of the tumors, discover the distant metastasis of the tumors in time, and provide more comprehensive disease assessment.

The invention belongs to the field of new application of medicines, and particularly relates to application of Sivelestat in preparation of cancer radiotherapy adjuvant medicines. According to the invention, Sivelestat which has been used for acute respiratory distress syndrome is creatively applied to tumor radiotherapy, and the Sivelestat inhibits the activity of neutrophil elastase and effectively blocks the formation of a neutrophil outer trapping net induced by radiotherapy, so that the invasion of tumor cells and the abnormal generation of blood vessels are inhibited, and an immunosuppression microenvironment is established. The application not only maintains the local killing effect of radiotherapy on primary tumors, but also cuts off the key path from radiotherapy to NETs to metastasis from the mechanism, and significantly reduces the risk of tumor recurrence and distant metastasis after radiotherapy. The traditional Chinese medicine composition has the transformation advantage of new use of old medicines, is clear in clinical safety, and is suitable for adjuvant therapy of various solid tumors.

The invention relates to the field of cancers, in particular to a colon cancer multi-mode collaborative treatment auxiliary system which comprises an LPDAM nano-platform, the LPDAM nano-platform comprises a medicine prepared from Lapacone, polydopamine and manganese ions, the medicine is applied to cancer cells, a photo-thermal module is used for acting on the cancer cells to which the LPDAM nano-platform is applied by utilizing a photo-thermal effect, and the LPDAM nano-platform is used for treating the cancer cells to which the LPDAM nano-platform is applied. A magnetic resonance module for magnetic resonance imaging of a patient whose cancer cells have been administered an LPDAM nanoplatform. By adopting the technical scheme of the invention, the Lapacone micelle can be modified by polydopamine to maintain the stability of the micelle, and manganese ions are chelated on the polydopamine to form the LPDAM nano platform with small and stable particle size, so that the primary tumor can be ablated, the distant metastasis and pulmonary metastasis of the tumor can be obviously reduced, and the toxic reaction of the whole body is not caused.

Endometrial cancer is classified and / or risk stratified using a suitably trained machine learning model. Risk classification of endometrial cancer is provided using a machine learning-based analysis of patient health data, such as clinicopathologic data, molecular data, and the like. Risk assessment is optimized for endometrial cancer, including risk of nodal involvement, distant metastasis, disease progression, and overall survival.

The present application relates to a method for constructing a prediction model for distant metastasis of nasopharyngeal carcinoma, and relates to the field of biomedicine. A method for constructing a prediction model for distant metastasis of nasopharyngeal carcinoma, wherein after collecting clinical nasopharyngeal carcinoma patient information and summarizing test data to obtain multi-dimensional test indicators, five main indicators with significant differences are screened through difference analysis and random forest analysis, and further PCA dimensionality reduction analysis is performed to obtain a principal component calculation formula, thereby obtaining N （PCA） Value; then N obtained by calculation （PCA） The calculation formula of N value is numerically deduced; the optimal calculation formula of N value, namely the prediction formula of distant metastasis of nasopharyngeal carcinoma, is determined by ROC analysis and verified by Spearman analysis; the N value calculated by the prediction formula of distant metastasis of nasopharyngeal carcinoma is output and used to assess the risk of distant metastasis of nasopharyngeal carcinoma.

The present invention relates to a composition comprising a skin keratinocyte-derived extracellular matrix as an active ingredient as an active ingredient for the prevention, alleviation, or treatment of cancer. The composition for preventing, alleviating, or treating cancer of the present invention contains an extracellular matrix derived from skin keratinocytes as an active ingredient, thereby significantly reducing only the proliferation of cancer cells without exhibiting side effects such as cytotoxicity in normal cells such as fibroblasts constituting the dermis of normal skin. In addition, the composition for preventing, alleviating, or treating cancer of the present invention was observed to: have the effect of suppressing the proliferation of MDA-MB-231, which cannot be expected to be greatly responsive to targeted therapies and currently lacks effective treatments, in addition to MCF7 among breast cancer cells; be able to remarkably inhibit the proliferation of Caki-1 and Caki-2, which are clear cell carcinomas classified as intractable cancer among kidney cancer cells and known to have many distant metastasis recurrences; and significantly reduce the proliferation of PANC-1, which is a pancreatic cancer cell line classified as refractory cancer that is difficult to detect early among cancer cells and is found in the late stage when surgery and treatment are limited, as well as having low treatment responsiveness to the latest immunotherapy drugs and low treatment responsiveness to targeted therapy and traditional chemotherapy. Furthermore, the composition for preventing, alleviating, or treating cancer of the present invention can be applied not only to breast cancer, kidney cancer, and pancreatic cancer, but also to the treatment of various carcinomas and solid cancers occurring on the skin. Moreover, the composition for preventing, alleviating, or treating cancer of the present invention can be used as a therapeutic agent in combination with other anticancer agents. Additionally, the composition for preventing, alleviating, or treating cancer of the present invention can be used in a treatment method for reducing the size of cancer before surgery without side effects, unlike traditional chemotherapy, through intratumoral injection.

To provide a therapeutic agent of cancer.SOLUTION: Provided are a progression inhibitory agent, a recurrence inhibitory agent and / or a therapeutic agent of solid cancer which contains a CD47 inhibitory substance as an active ingredient, and is administered in combination with standard therapy and immune checkpoint inhibitory substance, where the standard therapy is FOLFIRINOX therapy or low dose regimen thereof, the immune checkpoint inhibitory substance is Nivolumab, the CD47 inhibitory substance is Magrolimab, solid cancer is pancreatic cancer having distant metastasis.SELECTED DRAWING: None

The present invention discloses a miRNA biomarker for diagnosing or assisting the diagnosis of lung adenocarcinoma and its application, relating to the field of biomedicine. The invention also discloses a reagent for detecting target miRNAs in a sample and its application in preparing a product for diagnosing or assisting the diagnosis of lung adenocarcinoma. The target miRNAs include hsa-miR-3136-5p, hsa-miR-519d-5p, hsa-miR-381-5p, hsa-miR-490-5p, hsa-miR-377-5p, hsa-miR-320e, hsa-miR-2355-5p, and hsa-miR-6784-5p. The present invention screened out 8 key miRNAs and constructed an 8-miRNA risk scoring model including hsa-miR-3136-5p, hsa-miR-519d-5p, hsa-miR-381-5p, hsa-miR-490-5p, hsa-miR-377-5p, hsa-miR-320e, hsa-miR-2355-5p, and hsa-miR-6784-5p. The results showed that the 8-miRNA risk scoring model we constructed has the potential to predict distant metastasis in patients with lung adenocarcinoma.

The present invention discloses a circular RNA circTFDP2 and its siRNA application in the diagnosis and treatment of prostate cancer. The fluorescence quantitative PCR method finds that the expression of circTFDP2 in prostate cancer tissue is significantly increased, and the expression level is positively correlated with the Gleason score. The expression level of circTFDP2 detected in the urine of prostate cancer patients after prostate massage is positively correlated with the expression level of prostate cancer tissue. The expression level of circTFDP2 in prostate cancer cells is significantly higher than that in normal prostate epithelial cells. After overexpression, circTFDP2 can significantly promote the proliferation, migration and invasion of prostate cancer, as well as the tumor growth and distant metastasis of xenograft mouse tumor models in vivo. Targeted knockdown of circTFDP2 using siRNA can significantly inhibit the proliferation, migration, invasion and in vivo tumor growth and distant metastasis of prostate cancer cells. circTFDP2 plays an important role in the diagnosis and / or prognosis evaluation and treatment of prostate cancer, and can be used as a diagnostic biomarker and therapeutic target for prostate cancer.

The invention belongs to the field of kits, and particularly relates to application of a reagent for detecting HMGXB3 gene and protein expression level thereof in preparation of a kit for screening breast cancer metastasis or evaluating breast cancer prognosis. On the basis of early clinical discovery, in-vivo and in-vitro experiments and clinical data statistical analysis further verify that high expression of HMGXB3 can promote the distant metastasis behavior of the breast cancer, and the distant metastasis of the breast cancer can be inhibited after the HMGXB3 is knocked down; the invention also verifies that high expression of HMGXB3 can lead to obvious shortening of the total lifetime and the distant metastasis lifetime of the breast cancer patient, which provides an effective basis for the patient to take related treatment measures or decisions, and has a good clinical application prospect.

The invention discloses a composition, which comprises engineering bacteria for expressing TLS induced protein and mesenchymal stem cells, and can effectively induce TLS formation, inhibit tumor growth, improve systemic immunity, inhibit distant metastasis and prevent tumor recurrence in tumor tissues, thereby providing a new technical path for enhancing the universality and accessibility of immunotherapy. And an innovative platform is provided for the research on a combined treatment scheme of tumor immunotherapy.

The invention discloses application of TTK in prognosis prediction of an undifferentiated thyroid cancer, and provides a method for accurately evaluating prognosis of a patient with the undifferentiated thyroid cancer by calculating a predicted value through a formula according to the expression quantity of TTK in tumor tissues and whether distant metastasis exists in tumors. The technical operation is simple and convenient, and a basis can be provided for whether more positive measures need to be taken clinically to treat the patient suffering from the thyroid undifferentiated cancer, so that the prognosis of the patient suffering from the thyroid undifferentiated cancer is helped to be improved, unnecessary medical expenditure is avoided, and the defects in the prior art are overcome.

The invention belongs to the field of new application of drugs, and particularly relates to application of AZD5069 in preparation of cancer radiotherapy adjuvant drugs. The invention discloses a novel application of a CXCR2 receptor antagonist AZD5069 in preparation of an adjuvant drug for tumor radiotherapy. The invention aims to solve the core clinical problem that the tumor remote metastasis risk may be increased although the tumor can be locally killed by radiotherapy. Through combined application of AZD5069 and radiotherapy, collection and activation of neutrophile granulocytes activated by radiotherapy to a metastasis site can be inhibited by utilizing the capability of the AZD5069 for specifically blocking a CXCLs / CXCR2 signal channel, so that tumor metastasis is effectively prevented while the local curative effect of radiotherapy is maintained, and dual treatment targets of local control and whole body metastasis resistance are realized.

The invention discloses an establishment method and application of a mouse gastric cancer remote metastasis model, and the establishment method comprises the following steps: injecting a mouse gastric adenocarcinoma cell line MKC1 (Mus musculus) into a mouse body through intraperitoneal injection, portal intravenous injection, spleen injection or caudal intravenous injection, and feeding to obtain the mouse gastric cancer remote metastasis model. Compared with the prior art, the mouse gastric cancer distant metastasis model established in the invention has the advantages of strong repeatability in the construction process and good tumor formation stability, especially can form tumors in the C57BL / 6 mouse body with a sound immune system, and is suitable for research on gastric cancer distant metastasis molecular mechanism, immune microenvironment, chemotherapeutic drug resistance mechanism and the like.